olaparib
Researchers Aim to Confirm Benefits of Non-Hormonal Therapy for Certain Prostate Cancer Patients
Premium
Prostate cancer patients with BRCA2 and other homologous recombination repair mutations fared better on Lynparza than those without genomic alterations.
European Commission Approves AstraZeneca's Imfinzi Regimens Based on MMR Status
Depending on MMR status, endometrial cancer patients can receive first-line therapy with Imfinzi and chemo followed by Imfinzi alone or Imfinzi with Lynparza.
Io9 AI-Driven Digital Pathology Test Shows Potential to Inform Breast, Ovarian Cancer Therapy
Premium
The firm hopes to develop its DeepHRD digital pathology test as an alternative to costly companion diagnostics based on next-generation sequencing.
Keytruda Sales Climb 16 Percent in Q2 as Merck Pursues New Oncology Candidates
The drugmaker updated investors on its three-pronged strategy to diversify its pipeline and not overly rely on its top-selling blockbuster checkpoint inhibitor.
AstraZeneca Reports Encouraging Uptake of New Breast Cancer Drug Truqap in First Half of 2024
Premium
Despite a disappointing Phase III failure in triple-negative breast cancer, Truqap sales were strong in patients with biomarker-altered hormone-sensitive disease.